110. Cancer Res. 2018 Jul 1;78(13):3604-3618. doi: 10.1158/0008-5472.CAN-17-2405. Epub2018 Mar 20.Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T CellsDevoid of Immune Checkpoints.Gourdin N(1)(2)(3), Bossennec M(1)(2), Rodriguez C(1)(2)(3), Vigano S(4), Machon C(5)(6), Jandus C(4), Bauché D(2)(7)(8), Faget J(1)(2)(3), Durand I(2)(9), ChopinN(10), Tredan O(10), Marie JC(2)(7)(8), Dubois B(1)(2), Guitton J(5)(11), Romero P(4), Caux C(1)(2)(3), Ménétrier-Caux C(12)(2)(3).Author information: (1)Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre LéonBérard, Cancer Research Center of Lyon, Lyon, France.(2)Team 11, Immunology Virology Inflammation (IVI) Department, INSERM U-1052,Cancer Research Center of Lyon, Lyon, France.(3)Innovation and Translational Research Department, Centre Léon Bérard, Lyon,France.(4)Ludwig Cancer Research Center, Department of Oncology, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.(5)Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Laboratoire de Biochimieet Toxicologie, Pierre-Bénite, France.(6)Université de Lyon, Université Lyon 1, ISPB Faculté de pharmacie, Laboratoire de Chimie Analytique, Lyon, France.(7)TGF-β and Immuno-evasion Department of Immunology Virology and Inflammation,INSERM U1052, Cancer Research Center of Lyon, Lyon, France.(8)TGF-β and Immuno-evasion, Tumor immunology Program, DKFZ, Heidelberg, Germany.(9)Cytometry platform, INSERM U-1052, Cancer Research Center of Lyon, Lyon,France.(10)Centre Léon Bérard, Medical Oncology Department, Lyon, France.(11)Université de Lyon, Université Lyon 1, ISPB Faculté de pharmacie, Laboratoirede Toxicologie, Lyon, France.(12)Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS, Centre LéonBérard, Cancer Research Center of Lyon, Lyon, France.christine.caux@lyon.unicancer.fr.The production of CD73-derived adenosine (Ado) by Tregs has been proposed as aresistance mechanism to anti-PD-1 therapy in murine tumor models. We reportedthat human Tregs express the ectonucleotidase CD39, which generates AMP from ATP,but do not express the AMPase CD73. In contrast, CD73 defined a subset ofeffector CD4+ T cells (Teffs) enriched in polyfunctional Th1.17 cellscharacterized by expression of CXCR3, CCR6, and MDR1, and production ofIL17A/IFNγ/IL22/GM-CSF. CD39+ Tregs selectively targeted CD73+ Teffs throughcooperative degradation of ATP into Ado inhibiting and restricting the ability ofCD73+ Teffs to secrete IL17A. CD73+ Teffs infiltrating breast and ovarian tumors were functionally blunted by Tregs expressing upregulated levels of CD39 andATPase activity. Moreover, tumor-infiltrating CD73+ Teffs failed to expressinhibitory immune checkpoints, suggesting that CD73 might be selected underpressure from immune checkpoint blockade therapy and thus may represent anonredundant target for restoring antitumor immunity.Significance: PolyfunctionalCD73+ T-cell effectors lacking other immune checkpoints are selectively targeted by CD39 overexpressing Tregs that dominate the breast tumor environment. CancerRes; 78(13); 3604-18. ©2018 AACR.©2018 American Association for Cancer Research.DOI: 10.1158/0008-5472.CAN-17-2405 PMID: 29559470 